PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most common human malignancies worldwide with very poor prognosis. Resistance to targeted therapeutic drugs such as sorafenib remains one of the major challenges in clinical treatment. In the present study, PARP1 was found to be highly expressed in human...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xiao-Dong, Kong, Fan-En, Qi, Ling, Lin, Jia-Xin, Yan, Qian, Loong, Jane Ho Chun, Xi, Shao-Yan, Zhao, Yue, Zhang, Yan, Yuan, Yun-Fei, Ma, Ning-Fang, Ma, Stephanie, Guan, Xin-Yuan, Liu, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824946/
https://www.ncbi.nlm.nih.gov/pubmed/33485358
http://dx.doi.org/10.1186/s12943-021-01315-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824946/
https://www.ncbi.nlm.nih.gov/pubmed/33485358
http://dx.doi.org/10.1186/s12943-021-01315-9

Ejemplares similares